IL145487A0 - Apomorphine and sildenafil composition - Google Patents

Apomorphine and sildenafil composition

Info

Publication number
IL145487A0
IL145487A0 IL14548700A IL14548700A IL145487A0 IL 145487 A0 IL145487 A0 IL 145487A0 IL 14548700 A IL14548700 A IL 14548700A IL 14548700 A IL14548700 A IL 14548700A IL 145487 A0 IL145487 A0 IL 145487A0
Authority
IL
Israel
Prior art keywords
apomorphine
sildenafil
administered
treatment
sildenafil composition
Prior art date
Application number
IL14548700A
Other languages
English (en)
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of IL145487A0 publication Critical patent/IL145487A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14548700A 1999-03-16 2000-03-14 Apomorphine and sildenafil composition IL145487A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/270,035 US6087362A (en) 1999-03-16 1999-03-16 Apomorphine and sildenafil composition
PCT/US2000/006654 WO2000054774A1 (fr) 1999-03-16 2000-03-14 Composition d'apomorphine et de sildenafil

Publications (1)

Publication Number Publication Date
IL145487A0 true IL145487A0 (en) 2002-06-30

Family

ID=23029614

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14548700A IL145487A0 (en) 1999-03-16 2000-03-14 Apomorphine and sildenafil composition

Country Status (21)

Country Link
US (1) US6087362A (fr)
EP (1) EP1173178B1 (fr)
JP (1) JP2002539163A (fr)
CN (1) CN1350454A (fr)
AT (1) ATE302003T1 (fr)
AU (1) AU3744500A (fr)
BR (1) BR0009016A (fr)
CA (1) CA2367605A1 (fr)
CZ (1) CZ20013344A3 (fr)
DE (1) DE60022021T2 (fr)
DK (1) DK1173178T3 (fr)
ES (1) ES2244418T3 (fr)
HU (1) HUP0200549A3 (fr)
IL (1) IL145487A0 (fr)
MX (1) MXPA01009332A (fr)
NO (1) NO324511B1 (fr)
NZ (1) NZ514464A (fr)
PL (1) PL350313A1 (fr)
PT (1) PT1173178E (fr)
WO (1) WO2000054774A1 (fr)
ZA (1) ZA200107920B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
PL205279B1 (pl) * 2000-08-30 2010-03-31 Besins International Lab Zastosowanie żelu hydroalkoholowego zawierającego testosteron i zestaw do leczenia zaburzenia erekcji
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
EP1365740A1 (fr) * 2001-02-08 2003-12-03 Pharmacia Corporation Medicament a action rapide pour le traitement de dysfonctionnements sexuels
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP4450365B2 (ja) * 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
MXPA06013133A (es) * 2004-05-11 2007-05-23 Emotional Brain Bv Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
ES2553101T3 (es) * 2004-10-20 2015-12-04 Endorecherche Inc. Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas
ZA200803087B (en) 2005-10-12 2009-11-25 Unimed Pharmaceuticals Llc Improved testosterone gel and method of use
CA2677691C (fr) * 2007-02-12 2012-07-31 David Bar-Or Reduction des effets secondaires du tramadol
PL2120570T3 (pl) * 2007-02-12 2012-10-31 Vyrix Pharmaceuticals Inc Leczenie współwystępującego przedwczesnego wytrysku i zaburzenia wzwodu prącia
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
RU2547939C2 (ru) * 2007-12-26 2015-04-10 Биотест Аг Иммуноконъюгаты, направленные на cd138, и их применение
WO2009080829A1 (fr) * 2007-12-26 2009-07-02 Biotest Ag Agents ciblant cd138 et leurs applications
BRPI0821417A2 (pt) * 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
AR069979A1 (es) * 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
US20090246298A1 (en) * 2008-03-31 2009-10-01 Ceola P. Steele Viagra
US20100184722A1 (en) * 2008-12-19 2010-07-22 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
WO2010128087A2 (fr) * 2009-05-06 2010-11-11 Biotest Ag Utilisations d'immunoconjugués ciblant l'antigène cd138
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
DK2952191T3 (en) 2009-06-12 2018-12-10 Sunovion Pharmaceuticals Inc Sublingual apomorphine
WO2012000634A1 (fr) 2010-06-29 2012-01-05 Georg Bambach Composition pharmaceutique pour le traitement de dysfonction érectile
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CA3115378A1 (fr) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Films sublinguaux comprenant de l'apomorphine et une base organique
RU2632108C2 (ru) 2011-12-08 2017-10-02 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
EP3285771A4 (fr) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Méthodes de traitement de la maladie de parkinson par l'administration d'apomorphine à une muqueuse orale
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
EP0978282B1 (fr) * 1994-04-22 2005-12-14 Pentech Pharmaceuticals, Inc. Composition sublinguale d'apomorphine pour diagnostiquer l'impuissance fonctionnelle
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
EP0996447B1 (fr) * 1997-05-19 2006-07-19 Zonagen, Inc. Therapie combinatoire permettant de moduler la reponse sexuelle chez un patient
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
ZA200107920B (en) 2003-03-26
ATE302003T1 (de) 2005-09-15
PT1173178E (pt) 2005-11-30
BR0009016A (pt) 2002-04-16
WO2000054774A1 (fr) 2000-09-21
DE60022021T2 (de) 2006-06-08
CA2367605A1 (fr) 2000-09-21
DK1173178T3 (da) 2005-11-07
NO20014519L (no) 2001-10-25
AU3744500A (en) 2000-10-04
CZ20013344A3 (cs) 2002-08-14
ES2244418T3 (es) 2005-12-16
EP1173178A1 (fr) 2002-01-23
CN1350454A (zh) 2002-05-22
US6087362A (en) 2000-07-11
PL350313A1 (en) 2002-12-02
NO324511B1 (no) 2007-11-05
JP2002539163A (ja) 2002-11-19
HUP0200549A2 (hu) 2002-07-29
DE60022021D1 (de) 2005-09-22
NZ514464A (en) 2004-01-30
MXPA01009332A (es) 2002-06-21
EP1173178A4 (fr) 2002-09-04
EP1173178B1 (fr) 2005-08-17
NO20014519D0 (no) 2001-09-17
HUP0200549A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
PL350313A1 (en) Apomorphine and sildenafil composition
NZ540385A (en) Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer
HK1177901A1 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin 10--10- t
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
CA2582452A1 (fr) Doxorubicine liposomale pegylee en combinaison avec l'ecteinascidine 743
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
CA2368614A1 (fr) Traitement du cancer ameliore avec le temozolomide
JP2002540148A5 (fr)
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
CA2516458A1 (fr) Utilisation de composes de kahalalide pour la fabrication d'un medicament pour le traitement de psoriasis
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
PT1265629E (pt) Utilizacao da hormona de crescimento em dose baixa
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
BRPI0503488A (pt) agente de tratamento para sìndrome de intestino irritável com diarréia predominante